Integrated biotherapeutics Revenue and Competitors

Location

N/A

Total Funding

Fintech

Industry

Estimated Revenue & Valuation

  • Integrated biotherapeutics's estimated annual revenue is currently $6.8M per year.(i)
  • Integrated biotherapeutics's estimated revenue per employee is $117,000

Employee Data

  • Integrated biotherapeutics has 58 Employees.(i)
  • Integrated biotherapeutics grew their employee count by 7% last year.

Integrated biotherapeutics's People

NameTitleEmail/Phone
1
Associate Director, Bacterial TherapeuticsReveal Email/Phone
2
Project ManagerReveal Email/Phone
3
scientsReveal Email/Phone
4
Admin Assistant / PurchasingReveal Email/Phone
5
Research Associate IReveal Email/Phone
6
Research AssociateReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$1.4M180%N/AN/A
#2
$1.8M2033%N/AN/A
#3
$26M182-3%N/AN/A
#4
$2M2216%N/AN/A
#5
$30.7M2159%N/AN/A
#6
$2.5M288%N/AN/A
#7
$40.1M287-7%$158MN/A
#8
$26.9M1882%N/AN/A
#9
$1.5M196%N/AN/A
#10
$349.4M19204%N/AN/A
Add Company

What Is Integrated biotherapeutics?

Integrated BioTherapeutics Inc (IBT) is the 2009 Emerging Company of the Year in Maryland. IBT is a research-based company dedicated to development of vaccines and biotherapeutic molecules targeting emerging infectious agents. We are located in Gaithersburg, Maryland. Our primary areas of focus is on Ebola and Marburg viral hemorrhagic fevers and staph aureus. IBT is developing a panfilovirus vaccine under a contract with NIAID. In addition IBT is also testing an SEB vaccine in phase I trials sponsored by NIH. IBT has a close working arrangement with many of the United States government agencies including the United States Army Medical Research Institute of Infectious Diseases (USAMRIID), National Cancer Institute (NCI), National Institute of Health (NIH), and the Department of Defense (DOD). IBT Bioservices is our contract R&D services business. IBT Bioservices is developing screening assays and disease models to identify antiviral and antibacterial compounds and therapeutics for client companies. In addition, we offer contract testing using the Mesoscale Discovery platform by MSD. You can learn more about IBT Bioservices at www.ibtbioservices.com.

keywords:N/A

N/A

Total Funding

58

Number of Employees

$6.8M

Revenue (est)

7%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Integrated biotherapeutics News

2022-04-06 - Kiromic BioPharma Announces Availability of Company's ...

(NASDAQ: KRBP) (“Kiromic” or the “Company”), a clinical-stage fully integrated biotherapeutics company using its proprietary DIAMOND AI® (...

2022-03-30 - Kiromic BioPharma Reports Fourth Quarter and Full-Year ...

(NASDAQ: KRBP) (“Kiromic” or the “Company”), a clinical-stage fully integrated biotherapeutics company using its proprietary DIAMOND® artificial...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$14.1M58-5%N/A
#2
$13.3M584%N/A
#3
$12.9M59N/AN/A
#4
$17.2M5920%N/A
#5
$11.7M59-6%N/A